GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (NAS:QURE) » Definitions » E10

QURE (uniQure NV) E10 : $-2.88 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is uniQure NV E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

uniQure NV's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.910. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-2.88 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2025-03-03), uniQure NV's current stock price is $13.15. uniQure NV's E10 for the quarter that ended in Sep. 2024 was $-2.88. uniQure NV's Shiller PE Ratio of today is .


uniQure NV E10 Historical Data

The historical data trend for uniQure NV's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

uniQure NV E10 Chart

uniQure NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -2.28 -2.69

uniQure NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.63 -2.69 -2.78 -2.83 -2.88

Competitive Comparison of uniQure NV's E10

For the Biotechnology subindustry, uniQure NV's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


uniQure NV's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where uniQure NV's Shiller PE Ratio falls into.



uniQure NV E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, uniQure NV's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.91/131.6100*131.6100
=-0.910

Current CPI (Sep. 2024) = 131.6100.

uniQure NV Quarterly Data

per share eps CPI Adj_EPS
201412 -0.956 99.050 -1.270
201503 -0.747 99.750 -0.986
201506 -0.976 100.230 -1.282
201509 -1.215 100.500 -1.591
201512 -0.693 99.730 -0.915
201603 -0.900 100.310 -1.181
201606 -0.840 100.260 -1.103
201609 -0.610 100.570 -0.798
201612 -0.580 100.710 -0.758
201703 -0.800 101.440 -1.038
201706 -0.830 101.370 -1.078
201709 -0.400 102.030 -0.516
201712 -0.910 101.970 -1.175
201803 -0.590 102.470 -0.758
201806 -0.570 103.100 -0.728
201809 -0.590 103.950 -0.747
201812 -0.590 103.970 -0.747
201903 -0.740 105.370 -0.924
201906 -0.830 105.840 -1.032
201909 -0.580 106.700 -0.715
201912 -0.970 106.800 -1.195
202003 -0.630 106.850 -0.776
202006 -0.960 107.510 -1.175
202009 -1.210 107.880 -1.476
202012 -0.010 107.850 -0.012
202103 -0.910 108.870 -1.100
202106 8.510 109.670 10.212
202109 -0.790 110.790 -0.938
202112 0.170 114.010 0.196
202203 -1.000 119.460 -1.102
202206 -0.840 119.050 -0.929
202209 -1.020 126.890 -1.058
202212 0.150 124.940 0.158
202303 -1.630 124.720 -1.720
202306 -1.440 125.830 -1.506
202309 -1.880 127.160 -1.946
202312 -1.530 126.450 -1.592
202403 -1.360 128.580 -1.392
202406 -1.160 129.910 -1.175
202409 -0.910 131.610 -0.910

Add all the adjusted EPS together and divide 10 will get our e10.


uniQure NV  (NAS:QURE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


uniQure NV E10 Related Terms

Thank you for viewing the detailed overview of uniQure NV's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


uniQure NV Business Description

Traded in Other Exchanges
Address
Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Executives
Matthew C Kapusta director, officer: CEO, Managing Director 7358 MCVAY ROAD, GERMANTOWN TN 38138
Christian Klemt officer: Chief Financial Officer PAASHEUVELWEG 25A, AMSTERDAM P7 1105 BP
Walid Abi-saab officer: Chief Medical Officer C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 11058BP
Pierre Caloz officer: Chief Operating Officer UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 P7 11058BP
Robert Gut director C/O VERSARTIS, INC., 4200 BOHANNON DRIVE, SUITE 250, MENLO PARK CA 94025
Madhavan Balachandran director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Jeannette Potts officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Jeremy P. Springhorn director C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
Paula Soteropoulos director 49 WINONA STREET, PEABODY MA 01960
David D. Meek director 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Jack Kaye director C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Leonard E Post director
Ricardo Dolmetsch officer: President, R&D 113 HARTWELL AVENUE, LEXINGTON MA 02421
Kuta Alexander Edward Iii officer: Executive VP, Operations 239 WILLIS ROAD, SUDBURY MA 01776